Gilead Sciences Inc. (GILD-Q) Stock Predictions - Stockchase
WATCH LIST
227
Gilead Sciences Inc. (GILD-Q)

ON STOCKCHASE SINCE Dec 2008

biotechnology/pharmaceutical

Gilead Sciences Inc.

GILD-Q

44 watching          
Join the Discussion

Gilead Sciences Inc. (GILD-Q) SAVE Mar, 20, 2019, 6:16 am

65.49 0.47 (0.72%)

About Gilead Sciences Inc. (GILD-Q)

Gilead Sciences is an American biopharmaceutical company that discovers, develops and commercializes drugs. More at Wikipedia

What the experts are saying about GILD-Q



  • All
  • Filtered
Signal Opinion Expert
N/A
The pharmaceuticals and the health technology are not his skill set. The balance sheet is OK for a pharmaceutical. The analyst community seems to like it. (Analysts’ price target is $80.70)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
The pharmaceuticals and the health technology are not his skill set. The balance sheet is OK for a pharmaceutical. The analyst community seems to like it. (Analysts’ price target is $80.70)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Chris Stuchberr

Portfolio , Wellington-Altus Pri...

Price Price
$64.790
Owned Owned
Unknown

HOLD
He's owned this for four years, but it's struggled in the past two as they've transitioned from their hepatitis C drug era (limited growth). But they just announced great results on a new HIV drug. It's a value trap though looking cheap at 9x earnings. Pays a 3.8% dividend. They still generate lots of cash flow. He'd stick with it. At least you get that yield. Also, they just got a new CEO, so they're in transition.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He's owned this for four years, but it's struggled in the past two as they've transitioned from their hepatitis C drug era (limited growth). But they just announced great results on a new HIV drug. It's a value trap though looking cheap at 9x earnings. Pays a 3.8% dividend. They still generate lots of cash flow. He'd stick with it. At least you get that yield. Also, they just got a new CEO, so they're in transition.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$65.750
Owned Owned
Yes

DON'T BUY
Stay away. It's a broken chart. Simple as that. Also, there will be a wall of sellers on the way up, if and when it does go up.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Stay away. It's a broken chart. Simple as that. Also, there will be a wall of sellers on the way up, if and when it does go up.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$62.530
Owned Owned
Unknown

HOLD
Gilead Sciences Inc.(GILD-Q) 

December 21, 2018

He still likes it here and especially at these valuations. The new CEO will be good. They have announced a couple of new joint ventures and it is trading at less than 10 times earnings. Their HEP-C advantage has been declining, but they have growth in their HIV franchise.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He still likes it here and especially at these valuations. The new CEO will be good. They have announced a couple of new joint ventures and it is trading at less than 10 times earnings. Their HEP-C advantage has been declining, but they have growth in their HIV franchise.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$62.620
Owned Owned
Unknown

WATCH
Gilead Sciences Inc.(GILD-Q) 

December 3, 2018

A frustrating stock. They have expensive drugs, such as for hepatitis C. They failed to build out their franchise and not making acquisitions, and have only been doing that in the past few years. Their HIV franchise is doing quite well, though. They acquired Kite Pharma which could be a game-changer later. It's trading at 10x earnings. Upcoming catalysts are a liver study in Q1/Q2 could be positive. Maybe. But is GILD a value trap or opportunity? Buy it as its chart improves.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A frustrating stock. They have expensive drugs, such as for hepatitis C. They failed to build out their franchise and not making acquisitions, and have only been doing that in the past few years. Their HIV franchise is doing quite well, though. They acquired Kite Pharma which could be a game-changer later. It's trading at 10x earnings. Upcoming catalysts are a liver study in Q1/Q2 could be positive. Maybe. But is GILD a value trap or opportunity? Buy it as its chart improves.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$70.860
Owned Owned
Yes

TOP PICK
Gilead Sciences Inc.(GILD-Q) 

November 29, 2018

Value play. It's been hammered, trading at around 10X future PE, cheap. The market is valuing their HCV business to basically zero, and that's the side of the business that's been hurt with the generics coming out and pushing the prices lower. Their HIV business has been doing pretty well. New CEO coming in, they have $32B in cash and waiting to see how this cash will be spent. Yield 3.3%. (Analysts’ price target is $86.95)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Value play. It's been hammered, trading at around 10X future PE, cheap. The market is valuing their HCV business to basically zero, and that's the side of the business that's been hurt with the generics coming out and pushing the prices lower. Their HIV business has been doing pretty well. New CEO coming in, they have $32B in cash and waiting to see how this cash will be spent. Yield 3.3%. (Analysts’ price target is $86.95)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$69.690
Owned Owned
Yes

WAIT
Gilead Sciences Inc.(GILD-Q) 

November 26, 2018

Has had a pullback over the last 3 years. Their return on capital has gone down. They have had tough competition and some products going off patent. He would wait to see improved results before he decided on a position.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Has had a pullback over the last 3 years. Their return on capital has gone down. They have had tough competition and some products going off patent. He would wait to see improved results before he decided on a position.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Matt Kacur

President, FSA Financial Scienc...

Price Price
$66.530
Owned Owned
No

DON'T BUY
Gilead Sciences Inc.(GILD-Q) 

November 21, 2018

This is a US biotechnology company. They are big on treatments for HIV and hepatitis. It trades at a cheap valuation. There is competition from other big pharma and generics and biologics. It is reasonably cheap but depends on finding new markets for their drugs.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
This is a US biotechnology company. They are big on treatments for HIV and hepatitis. It trades at a cheap valuation. There is competition from other big pharma and generics and biologics. It is reasonably cheap but depends on finding new markets for their drugs.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Michael Simpson

Senior Vic, Sentry Investments...

Price Price
$66.740
Owned Owned
No

BUY
Gilead Sciences Inc.(GILD-Q) 

October 29, 2018

Has long owned it and likes it. They had some bad years when they overpriced their hepatitis C drug and received bad press. They also sell HIV and heart drugs, sectors that are growing. They increased their guidance last week, a rarity these days. At 10x earnings, he'd buy it, not sell it. One overhang is that their CEO is leaving.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has long owned it and likes it. They had some bad years when they overpriced their hepatitis C drug and received bad press. They also sell HIV and heart drugs, sectors that are growing. They increased their guidance last week, a rarity these days. At 10x earnings, he'd buy it, not sell it. One overhang is that their CEO is leaving.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$70.900
Owned Owned
Yes

TOP PICK
Gilead Sciences Inc.(GILD-Q) 

September 27, 2018

The valuation continues to get lower and lower.  They have a lot of cash.  Their HEP-C and HIV businesses were 50/50 and now the HEP-C business is only 25%.  The new CEO coming is to spend some of the cash intelligently.  (Analysts’ target: $88.05).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The valuation continues to get lower and lower.  They have a lot of cash.  Their HEP-C and HIV businesses were 50/50 and now the HEP-C business is only 25%.  The new CEO coming is to spend some of the cash intelligently.  (Analysts’ target: $88.05).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Kash Pashootan

CEO & Chie, First Avenue Investm...

Price Price
$76.580
Owned Owned
Yes

PAST TOP PICK

(A Top Pick August 3/2017, Up 8%) Recently exited and bought JNJ instead. Hurt by own success with drugs that cure. Great for society, but not great for the equity. Waiting for transitional acquisition that’s not coming.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick August 3/2017, Up 8%) Recently exited and bought JNJ instead. Hurt by own success with drugs that cure. Great for society, but not great for the equity. Waiting for transitional acquisition that’s not coming.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Gardner, C

Partner an, Avenue Investment Ma...

Price Price
$33.510
Owned Owned
No

WATCH

It has had a long, long downtrend and recently found its footing, hitting his downside target of four times book value.  $65 would be a good floor on this stock at which point you buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

It has had a long, long downtrend and recently found its footing, hitting his downside target of four times book value.  $65 would be a good floor on this stock at which point you buy.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ross Healy

Chairman, Strategic Analysis C...

Price Price
$76.320
Owned Owned
Unknown

BUY

Looking at the graph it has been in a very difficult position in the last coupe of years. They essentially cured hepatitis C. It was an expensive drug. $98,000 per patient. It has come off patent. Competitors came to produce it now. They have been on the penalty box for the past year and a half. But they are making inroads on other drugs. They have had meaningful trials. At this value there is a good opportunity. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Looking at the graph it has been in a very difficult position in the last coupe of years. They essentially cured hepatitis C. It was an expensive drug. $98,000 per patient. It has come off patent. Competitors came to produce it now. They have been on the penalty box for the past year and a half. But they are making inroads on other drugs. They have had meaningful trials. At this value there is a good opportunity. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$72.810
Owned Owned
Yes

TOP PICK

Gilead is trading at 10.5x next year's earnings, and just increased its dividend. They're losing sales on their hepatitis C franchise which was a winner for them three years ago. But they have advances in oncology through a recent purchase. Good, new drug products are coming out which could lead to growth. Lots of free cash flow and some buybacks. They need, however, growth to justify high valuations. This will be a slow road, but a good one. (Analysts' price target: $85.72)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Gilead is trading at 10.5x next year's earnings, and just increased its dividend. They're losing sales on their hepatitis C franchise which was a winner for them three years ago. But they have advances in oncology through a recent purchase. Good, new drug products are coming out which could lead to growth. Lots of free cash flow and some buybacks. They need, however, growth to justify high valuations. This will be a slow road, but a good one. (Analysts' price target: $85.72)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$68.640
Owned Owned
Yes

WATCH

It has been in the news a lot.  They own technology that is a cure for Hep-C.  There is a lot of controversy as they are expensive and a cure costs about $90,000.  Lobby groups have negotiated better pricing.  It has had huge cash flow and great earnings but is falling dramatically. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

It has been in the news a lot.  They own technology that is a cure for Hep-C.  There is a lot of controversy as they are expensive and a cure costs about $90,000.  Lobby groups have negotiated better pricing.  It has had huge cash flow and great earnings but is falling dramatically. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$71.900
Owned Owned
No

Showing 1 to 15 of 227 entries
Successfully Saved Company
Successfully Saved Company
6+
JOIN THE DISCUSSION
6 comments in the last 7 days